Valuation: VolitionRx Limited

Market Cap 4.48M 3.87M 3.63M 3.3M 6.21M 428M 6.31M 42.57M 16.65M 214M 16.81M 16.44M 712M P/E 2026 *
-0.24x
P/E 2027 * -0.39x
Enterprise Value 4.48M 3.87M 3.63M 3.3M 6.21M 428M 6.31M 42.57M 16.65M 214M 16.81M 16.44M 712M EV / Sales 2026 *
1.81x
EV / Sales 2027 * 0.78x
Free-Float
83.28%
Yield 2026 *
-
Yield 2027 * -
1 day-14.78%
1 week-30.68%
Current month-25.16%
1 month-54.46%
3 months-73.13%
6 months-88.15%
Current year-89.49%
1 week 0.53
Extreme 0.53
0.79
1 month 0.53
Extreme 0.53
1.19
Current year 0.53
Extreme 0.53
7.73
1 year 0.53
Extreme 0.53
14.8
3 years 0.53
Extreme 0.53
27.6
5 years 0.53
Extreme 0.53
82.8
10 years 0.53
Extreme 0.53
136.8
Manager TitleAgeSince
Chief Executive Officer 55 2011-10-05
Director of Finance/CFO 56 2021-01-31
Chief Tech/Sci/R&D Officer 49 2024-03-31
Director TitleAgeSince
Director/Board Member 55 2011-10-05
Director/Board Member 77 2011-10-05
Director/Board Member 64 2019-10-08
Date Insider Type Main position Quantity % Market Cap.
3/17/26 Tax

Chief Technology Officer

5,310 0.0039%
3/17/26 Tax

Company Secretary

3,948 0.0029%
3/1/26
Concord International, Inc.
OtherCompany 0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-14.78%-30.68%-96.13%-97.78% 4.48M
+1.14%-0.76%+89.72%+293.32% 3.95B
-3.17%-12.64%+36.50%+64.80% 3.32B
+7.06%+10.09%+173.73%-7.06% 3.16B
-4.35%-2.93%+282.77%+369.15% 2.34B
-3.10%+1.70%-21.24%-25.97% 2.31B
-0.43%+3.68%+9.37% - 1.3B
+0.78%+11.25%+15.23%+49.19% 1.04B
-1.38%-8.51%+118.39%-45.09% 849M
+29.91%+22.82%-6.81%+358.96% 616M
Average +1.17%-1.00%+60.15%+106.61% 1.89B
Weighted average by Cap. +0.87%-0.64%+93.28%+135.85%

Financials

2026 *2027 *
Net sales 2.48M 2.14M 2.01M 1.83M 3.44M 237M 3.49M 23.56M 9.21M 119M 9.3M 9.1M 394M 5.73M 4.95M 4.65M 4.23M 7.96M 548M 8.09M 54.52M 21.32M 275M 21.53M 21.06M 912M
Net income -22.2M -19.18M -18.02M -16.39M -30.81M -2.12B -31.32M -211M -82.55M -1.06B -83.36M -81.55M -3.53B -19.62M -16.94M -15.92M -14.48M -27.23M -1.88B -27.67M -187M -72.95M -939M -73.66M -72.06M -3.12B
Net Debt - -
Logo VolitionRx Limited
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
-
Date Price Change Volume
26-08-14 US$0.5374 -14.78% 958,494
26-08-13 US$0.6306 -5.68% 839,813
26-08-12 US$0.6686 -6.52% 1,918,153
26-08-11 US$0.7152 -6.75% 693,595
26-08-10 US$0.7670 -1.07% 344,476
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.5374USD
Average target price
16.97USD
Spread / Average Target
+3,057.05%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VNRX Stock